rituximab,glofitamab,ibrutinib,Bendamustine,Obinutuzumab 
biogen,roche,novartis,janssen,abbvie
['dlbcl', 'glofitamab', 'shine', 'cll', 'lymphoma']
hem docs: lymphoma &amp; cll, 1 pm e450 glofitamab: bispecifoc t cell engager cd20-cd3 in r/r dlbcl &amp; ibrutinib+br phase 3 shine study in mcl evolving treatment landscape in cll 4:30 pm, s100a. also #asco_new_drug_session
Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet is not endorsement